Crossmark

A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth

Published Online: 2021-01-03

Published Print: 2021-04

Authors

Bai, Chenguang

Xu, Yi

Qiu, Cen https://orcid.org/0000-0002-3114-1901
Funding

Funding for this research was provided by:

Fundamental Research Programme funding of Ninth People's Hospital affiliated to the Shanghai Jiao Tong University School of Medicine (No. JYZZ068)
License Information

Text and Data Mining valid from 2021-01-03

Version of Record valid from 2021-01-03
More Information

Article History

Received: 15 August 2020

Accepted: 2 December 2020

First Online: 3 January 2021

Compliance with ethical standards

:

: The authors declare that they have no competing interests.

: The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by Ethics Committee and Animal Ethics Committee of Ninth People's Hospital affiliated Shanghai Jiao Tong University School of Medicine. The approval numbers were SH9H-2020-TK66-1 and SH9H-2020-A142-1.

: Informed consents were obtained from all patients for the use of their samples.

Document is current